Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : and TOA EIYO Announce Termination of Distribution Agreement

04/04/2021 | 08:02pm EDT

Press Release

Astellas and TOA EIYO Announce Termination of

Distribution Agreement

TOKYO, April 5, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji

Yasukawa, Ph.D., "Astellas" ) and TOA EIYO Ltd. (President: Atsuo Takahashi, Ph.D., "TOA EIYO") today announced that the both companies have agreed to terminate the distribution agreement on March 31, 2022. In accordance with this agreement, after April 1, 2022, TOA EIYO will independently sell and provide information on all 18 products such as Bisono® tape, a transdermal patch of β1 blocker, for treatment of hypertension and atrial fibrillation and Frandol® tablets and tape for treatment of ischemic heart disease, which TOA EIYO obtained Marketing Authorization in Japan, that are currently sold on consignment by Astellas.

Astellas and TOA EIYO has collaborated for sales and marketing for a long time. Astellas currently sells most of the products which TOA EIYO obtained Marketing Authorization in Japan, and TOA EIYO provides their product information to medical institutions. The both companies have discussed and agreed to terminate the distribution agreement on March 31, 2022.

Astellas is continuously working on optimizing the allocation of management resouces in order to maximize the value of each product, and the termination of the distribution agreement is part of this effort. As a specialty pharmaceutical company in the field of cardiovascular medicine, TOA EIYO has decided that it is necessary to establish its own sales structure of products in order to meet the diverse needs of cardiovasculartreatment.

Astellas and TOA EIYO will work closely during the sales transfer process to ensure stable supply of the relevant products and a smooth continuation of activities, including the provision/collection of product information and the promotion of their proper use.

1

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

About TOA EIYO

TOA EIYO Ltd., based in Tokyo, Japan, is a company dedicated to contributing to the health of people through unique medicines primarily in the cardiovascular fields. TOA EIYO aims to be a specialized pharmaceutical company that is truly indispensable to the medical front lines via our research and development of new medicines and value-added generic drugs in the cardiovascular fields including ischemic heart disease, arrhythmia and heart failure, and other related fields. For more information, please visit our website at https://www.toaeiyo.co.jp/english/

Cautionary Notes (Astellas)

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

2

TOA EIYO Ltd.

General Affairs Section

TEL: +81-3-5542-8800 FAX: +81-3-5542-8743

3

Disclaimer

Astellas Pharma Inc. published this content on 05 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2021 00:01:03 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
PU
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
BU
06/29ASTELLAS PHARMA : Corporate Governance Report
PU
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Ad..
PU
More news
Financials
Sales 2022 1 320 B 11 953 M 11 953 M
Net income 2022 204 B 1 848 M 1 848 M
Net cash 2022 425 B 3 846 M 3 846 M
P/E ratio 2022 17,3x
Yield 2022 2,55%
Capitalization 3 561 B 32 214 M 32 253 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,09x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 912,00 JPY
Average target price 2 470,77 JPY
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.19.95%33 619
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246